Spyre Therapeutics, Inc. (SYRE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Research Workspace
Put SYRE beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Advance Phase 2 SKYLINE trial for SPY001: SPY072 SKYWAY-RA topline results mixed (Aug 2026); SPY001 SKYLINE trial progress unconfirmed vs 2026-Q4 target.
View ThesisManagement screens weak on capital allocation, margins.
View ManagementModerate volatility — typically moves about 2% a day.
View RiskSYRE's growth depends on advancing its Phase 2 SKYLINE trial for SPY001. Recent results were mixed, which raises concerns about future progress. Revenue grew steadily, and the last quarter beat expectations. It trades at 555× sales versus a peer median of 11×. This significant premium suggests the market expects strong future growth. If guidance is cut on the next call, the stock could decline further. Peer multiples imply a price about 14% above where it trades. This read is provisional.
Trailing returns as of 2026-09-04. SYRE is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 17 analysts currently covering SYRE (as of Sep 2026).
Based on 7 Wall Street analysts offering 12-month price targets for SYRE in the last 4 months.
Continue this research
Compare SYRE with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| SYRE Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 2 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put SYRE next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Focus on long-acting antibodies for IBD and rheumatic diseases
Mixed results may hinder long-acting antibody focus.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $88.98
The last 12 months of price, then the range of analyst 12-month targets from today’s $88.98.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.

Threatens: Advance Phase 2 SKYLINE trial for SPY001
Stock tumble indicates investor concern over trial outcomes.

Analyst maintains buy rating, supporting positive outlook.